Many tumour- and bone-derived factors that have been implicated in the pathogenesis of breast cancer bone metastases including receptor activator of NFκB ligand (RANKL) and interleukin-1 (IL-1) activate NFκB [12–14]. The gene discussed is TNFSF11; the disease is neoplasm.